ASCO
Most Read
Amgen’s drug — targeting an ‘undruggable’ cancer protein — shrank tumors in half of patients
Merck’s R&D boss sees more promise in his big drug and a $1 billion deal
Forget controversy. AstraZeneca’s dynamic duo wants to dominate the market for cancer drugs
Moderna makes ASCO debut with an early look at a personalized cancer vaccine
Novartis hopes new survival data will help its Kisqali take on Pfizer’s Ibrance. It probably won’t
The Affordable Care Act erased a racial disparity in cancer care, a new study says
